Janssen Demonstrates Its Commitment to Advancing Transformative Solutions for Multiple Sclerosis at ACTRIMS Forum 2022

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that 13 company-sponsored data presentations from its multiple...

Related Keywords

Florida ,United States ,West Palm Beach ,Prinzj Ponesimod ,Jessica Moore ,Bill Martin ,None Of The Janssen Pharmaceutical Companies ,Genentech ,Americas Committee For Treatment ,Janssen Pharmaceuticals Inc ,National Multiple Sclerosis Society ,Janssen Research Development ,Janssen Pharmaceutical Companies ,Janssen Pharmaceutical Companies Of Johnson ,Actelion Pharmaceuticals Ltd ,Exchange Commission ,Companies Of Johnson ,Idorsia Pharmaceuticals Ltd ,Research In Multiple Sclerosis ,Johnson ,Multiple Sclerosis ,Global Therapeutic Area Head ,Janssen Research ,Data Presentations Include ,Patient Perspectives ,Patient Burden Related ,Hidden Symptoms ,Novel Patient Recruitment Strategy ,Up Front Matching ,Mimic Randomization ,Phosphate Receptor ,Relapsing Forms ,Long Term Pooled Safety Results From ,Clinical Development ,Its Application ,Clinical Outcome Assessment ,Disease Modifying Therapy ,Patients With Relapsing Multiple Sclerosis ,Results From ,Ponesimod Compared With Teriflunomide ,Female Patients With Relapsing Multiple ,Patients Treated With ,Cingulum Demyelination ,First Dose Cardiac Observation ,Patients Taking ,Real World Study Characterizing Impact ,Patient Symptom Recall ,Adults With Relapsing Multiple ,Systematic Literature Review ,Patient Reported Fatigue ,Disease Modifying Therapies ,Treatment Decision ,Starter Pack ,Posterior Reversible Encephalopathy Syndrome ,Janssen Pharmaceuticals ,Pharmaceutical Companies ,Infectious Diseases ,Private Securities Litigation Reform Act ,Annual Report ,Note Regarding Forward Looking ,Quarterly Report ,Ther Adv Chronic ,Multiple Sclerosis Society ,Mult Scler Relat ,Janssen Pharmaceutical Companies Of Johnson Amp ,